Urge the FDA to expedite and continue evaluating rapid-acting novel therapeutics, including entactogen- and psychedelic-assisted therapies, for serious mental health conditions.

we respectfully urge the FDA to continue its evaluation of entactogen- and psychedelic-assisted therapies with transparency, urgency, and scientific rigor

Bergman joined a letter asking FDA to speed and continue review of breakthrough mental health therapies.

Bergman, Correa Lead Letter Urging FDA to Expedite Review of Breakthrough Mental Health Therapies | U.S. Representative Jack Bergman
primary · press_release · model gpt-5.4-mini

Reps. Jack Bergman and Lou Correa, co-chairs of the Congressional Psychedelics Advancing Therapies Caucus, led 30 bipartisan colleagues in sending a letter to Food and Drug Administration (FDA) Commissioner Martin A. Makary urging the agency to advance its evaluation of rapid-acting novel therapeutics – including entactogen- and psychedelic-assisted therapies – for the

Led a letter urging the FDA to speed evaluation of psychedelic and other rapid-acting mental health therapies.

Press Releases | U.S. Representative Jack Bergman
primary · other · model gpt-5.4-mini

On May 6, 2026, Bergman’s office said Bergman and Correa led 30 bipartisan colleagues in sending a letter to FDA Commissioner Martin A. Makary urging the agency to advance its evaluation of rapid-acting novel therapeutics, including entactogen- and psychedelic-assisted therapies, for serious mental health conditions. The letter asks for written responses on FDA methodology, review expertise, and the timeline for finalizing the June 2023 psychedelic-drugs guidance.

Concrete advocacy action in the lookback window: a bipartisan congressional letter directly urging FDA expedited evaluation and continued guidance work. This is effort, not delivery.

unresolved same_term A for effort

Bergman, Correa Lead Letter Urging FDA to Expedite Review of Breakthrough Mental Health Therapies | U.S. Representative Jack Bergman
primary · model gpt-5.4-mini · confidence 98%

FDA announced it was accelerating research, approval, and responsible access to promising mental health treatments, prioritizing therapies with Breakthrough Therapy designation and issuing national priority vouchers for psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD. FDA also said it intended to release final guidance imminently for sponsors developing these products.

Official agency action consistent with the claim’s aim. It indicates partial delivery by the FDA itself, though not necessarily as a direct result of Bergman’s request. The agency actions include expedited development pathways and continued evaluation for psychedelic-related therapies.

partial same_term

FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order | FDA
secondary · model gpt-5.4-mini · confidence 90%

Bergman and Correa led 30 bipartisan House members in a letter to FDA Commissioner Martin A. Makary urging the agency to advance evaluation of rapid-acting novel therapeutics, including entactogen- and psychedelic-assisted therapies, and asking for the timeline to finalize the June 2023 guidance.

Direct congressional advocacy for the claimed FDA action, showing meaningful effort but not delivery by the member.

unresolved same_term A for effort

Bergman, Correa Lead Letter Urging FDA to Expedite Review of Breakthrough Mental Health Therapies | U.S. Representative Jack Bergman
primary · model gpt-5.4-mini · confidence 98%

The FDA announced priority vouchers for psilocybin studies, allowed an early phase noribogaine study to move forward, and said it intended to release final guidance imminently for sponsors developing these products.

Agency action consistent with faster evaluation of psychedelic-related therapies, supporting partial fulfillment of the underlying policy goal.

partial same_term

FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order | FDA
secondary · model gpt-5.4-mini · confidence 92%

Rep. Jack Bergman's office announced that Bergman and Rep. Lou Correa led 30 bipartisan House colleagues in a letter to FDA Commissioner Martin A. Makary urging FDA to advance evaluation of rapid-acting novel therapeutics, including entactogen- and psychedelic-assisted therapies, for serious mental health conditions. The release reproduces the letter asking about FDA methodology, review expertise, interagency coordination, and timing for final guidance.

This official House release directly documents Bergman doing the promised oversight action: urging FDA to expedite and continue evaluating the specified therapies.

delivered same_term

Bergman, Correa Lead Letter Urging FDA to Expedite Review of Breakthrough Mental Health Therapies | U.S. Representative Jack Bergman
primary · model gpt-5.5 · confidence 98%

The signed congressional letter begins by addressing FDA's ongoing evaluation of rapid-acting novel therapeutics, including entactogen- and psychedelic-assisted therapies. It states agreement that FDA should conduct expeditious and rapid review for promising treatments addressing urgent unmet needs, asks when FDA will finalize its June 2023 guidance, and closes by urging FDA to continue evaluation with transparency, urgency, and scientific rigor. Jack Bergman is listed as a signer.

The primary letter text is the strongest proof of fulfillment because the promise was to urge FDA, and Bergman did so in writing during the relevant House term.

delivered same_term

May 1, 2026 letter to FDA Commissioner Martin A. Makary regarding FDA evaluation of entactogen- and psychedelic-assisted therapies
secondary · model gpt-5.5 · confidence 99%

FDA announced regulatory actions supporting development of serotonin-2A agonists and related psychedelic products, including priority vouchers for psilocybin and methylone studies, an allowed early phase noribogaine clinical study, continued data review, and imminent final guidance for sponsors developing these products.

FDA action supports the policy direction of expedited and continued evaluation, though it occurred before Bergman's May 2026 letter and is not necessary to credit the member's promise to urge FDA.

partial same_term

FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order | FDA
secondary · model gpt-5.5 · confidence 90%

Executive Order 14401 states a policy to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs for serious mental illness. It directs FDA review prioritization for appropriate psychedelic drugs with Breakthrough Therapy designation and calls for HHS, FDA, and VA collaboration to facilitate timely evaluation and approval where statutory standards are met.

The executive order corroborates that the federal government was moving in the same policy area during the same term, but Bergman's own fulfillment rests on his subsequent FDA oversight letter.

partial same_term

Accelerating Medical Treatments for Serious Mental Illness | The White House
secondary · model gpt-5.5 · confidence 86%